Atracurium
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
Kanamycin
Aminoglycoside · Antibiotic
AminoglycosideAntibioticATC null
CDSCO approvedSchedule H1
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
- AtracuriumSevereDatabaseDDInter
- BacitracinSevereDatabaseDDInter
- Botulinum Toxin Type ASevereDatabaseDDInter
- Botulinum Toxin Type BSevereDatabaseDDInter
Mechanism
Kanamycin, an aminoglycoside antibiotic, exerts its antibacterial effects by binding to the 30S ribosomal subunit of susceptible bacteria. This binding interferes with protein synthesis, leading to misreading of the mRNA code and premature termination of protein translation. This disruption of essential bacterial protein production results in bactericidal activity.
Indications
Preoperative preparation of the colon (in combination with other agents)Treatment of drug-susceptible tuberculosis (as an alternative to streptomycin when resistance is common or as a fourth drug in initial therapy if drug resistance is a concern)hard-to-treat nontuberculous mycobacterial infectionsdrug-resistant mycobacterium avium complexmycobacterium abscessussecond line drug in resistant tuberculosis (occasionally)gram-negative bacillary infections (only if mandated by sensitivity report)MDR-TB (included in the regimen during the intensive phase)
Dosing
- Adult
- Bexsero vaccine suspension for injection 0.5ml pre-filled syringes |. Trumenba vaccine suspension for injection 0.5ml pre-filled syringes |. Child 1–17 years: 0.5 mL for 1 dose, dose to be given. ▶ Adult 18–24 years: 0.5 mL for 1 dose, dose to be given. NeisVac-C vaccine suspension for injection 0.5ml pre-filled syringes |
- Renal adjustment
- CLcr (ml/min) 70 -> 70% daily, 50 -> 50% daily, 30 -> 30% daily, 20–30 -> 80% alternate day, 10–20 -> 60% alternate day, <10 -> 40% alternate day
Pharmacokinetics
Half-life
2–4 hours (plasma)
Protein binding
clinically insignificant
Excretion
excreted unchanged in urine by glomerular filtration
Contraindications
- pregnancy
- perforated eardrum (ear drops)
Side effects
Common
hearing loss (irreversible, more common than vestibular disturbance)nephrotoxicity
Serious
- Nephrotoxicity (with parenteral administration)
- Ototoxicity (with parenteral administration)
- irreversible hearing loss (dose- and duration-dependent)
- vestibular damage (dose- and duration-dependent)
- Ototoxicity (less vestibular toxicity than hearing loss)
- Nephrotoxicity
- Nephrotoxicity (usually reversible)
- Ototoxicity (vestibular and cochlear, may be irreversible)
Pregnancy & lactation
Pregnancy
D
Drug interactions
Bacitracin
Severe
Database
Clinical effect not specified
Source: DDInter
Botulinum Toxin Type A
Severe
Database
Clinical effect not specified
Source: DDInter
Botulinum Toxin Type B
Severe
Database
Clinical effect not specified
Source: DDInter
Bumetanide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Capreomycin
Severe
Database
Clinical effect not specified
Source: DDInter
Cidofovir
Severe
Database
Clinical effect not specified
Source: DDInter
Cisatracurium
Severe
Database
Clinical effect not specified
Source: DDInter
Colistimethate
Severe
Database
Clinical effect not specified
Source: DDInter
Deferasirox
Severe
Database
Clinical effect not specified
Source: DDInter
Diatrizoate
Severe
Database
Clinical effect not specified
Source: DDInter
Doxacurium
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Drug-resistant tuberculosis
RNTCP · Pulmonology · 2025
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Antimicrobial resistance — clinical roadmap
MOHFW · Infectious Diseases · 2012
Extrapulmonary tuberculosis
ICMR · Infectious Diseases · 2022
Pulmonary tuberculosis
RNTCP · Infectious Disease · 2023
Other Aminoglycoside drugs
Ask House about Kanamycin
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Harrison 22e, BNF·Verified: 2026-05-10 · House clinical team